comparemela.com
Home
Live Updates
Dr Tarantino on the Expansion of Treatment Options Post-CDK4
Dr Tarantino on the Expansion of Treatment Options Post-CDK4
Dr Tarantino on the Expansion of Treatment Options Post-CDK4/6 Inhibition in HR+ Breast Cancer
Paolo Tarantino, MD, discusses the expansion and selection of effective treatment options for patients with hormone receptor-positive breast cancer who progressed on a CDK 4/6 inhibitor.
Related Keywords
Paolo Tarantino ,
Dana Farber Cancer Institute ,
European Institute Of Oncology ,
European Institute ,
Breast Cancer ,
Onclive Tv ,
Ost Cdk4 6 ,
Hormone Receptor Positive Breast Cancer ,
Elacestrant ,
Alpelisib ,
Fulvestrant ,
Everolimus ,